Chemed vs NeoGenomics: why the prices moved differently

Weekly · monthly · quarterly news summaries, side by side in time

Chemed Corp (CHE)

Q3 202624 Jul – 27 Aug 2026

▲3▼1

Chemed's strong Q2 and raised guidance outweigh a bearish call

Q2 profit jumps and full-year guidance raised Chemed's second-quarter profit rose to $67.7 million ($5.13 per share) from $52.5 million, with revenue up 8.8% to $673 million. Management raised 2026 adjusted EPS guidance to $25.00-$25.75 and lifted the revenue growth outlook, signaling the business is performing better than expected.
This is the core new event that directly lifts earnings expectations and the stock.
Vitas hospice drives growth; Roto Rooter lags The Vitas hospice unit beat expectations with 9% more admissions and lower labor costs, boosting revenue and margins. Roto Rooter's plumbing segment was weaker, with fewer leads and a drop in water restoration revenue, but management is reducing its reliance on paid leads.
Explains the operational engine behind the earnings beat and the one soft spot investors should watch.
Dividend raised 17% and buybacks continue Chemed raised its quarterly dividend by 17% to 70 cents per share and is repurchasing shares aggressively, funded by over $173 million in quarterly operating cash flow. Returning more cash to shareholders supports the stock price and signals confidence in future profits.
Shows a concrete new capital return action that supports the shares.
Bearish call flags slow long-term growth A StockStory report named Chemed a healthcare stock to avoid, citing just 4% annual revenue growth and 2.8% EPS growth over five years, plus diminishing returns on capital. This is a counterweight to the upbeat earnings and could cap gains if investors focus on the slow long-term track record.
Provides the main negative view that balances the positive earnings news.

August 202624 Jul – 27 Aug 2026

▲3▼1

Chemed's strong Q2 and raised guidance outweigh a bearish call

Q2 profit jumps and full-year guidance raised Chemed's second-quarter profit rose to $67.7 million ($5.13 per share) from $52.5 million, with revenue up 8.8% to $673 million. Management raised 2026 adjusted EPS guidance to $25.00-$25.75 and lifted the revenue growth outlook, signaling the business is performing better than expected.
This is the core new event that directly lifts earnings expectations and the stock.
Vitas hospice drives growth; Roto Rooter lags The Vitas hospice unit beat expectations with 9% more admissions and lower labor costs, boosting revenue and margins. Roto Rooter's plumbing segment was weaker, with fewer leads and a drop in water restoration revenue, but management is reducing its reliance on paid leads.
Explains the operational engine behind the earnings beat and the one soft spot investors should watch.
Dividend raised 17% and buybacks continue Chemed raised its quarterly dividend by 17% to 70 cents per share and is repurchasing shares aggressively, funded by over $173 million in quarterly operating cash flow. Returning more cash to shareholders supports the stock price and signals confidence in future profits.
Shows a concrete new capital return action that supports the shares.
Bearish call flags slow long-term growth A StockStory report named Chemed a healthcare stock to avoid, citing just 4% annual revenue growth and 2.8% EPS growth over five years, plus diminishing returns on capital. This is a counterweight to the upbeat earnings and could cap gains if investors focus on the slow long-term track record.
Provides the main negative view that balances the positive earnings news.

Latest24 Jul – 27 Aug 2026

▲3▼1

Chemed's strong Q2 and raised guidance outweigh a bearish call

Q2 profit jumps and full-year guidance raised Chemed's second-quarter profit rose to $67.7 million ($5.13 per share) from $52.5 million, with revenue up 8.8% to $673 million. Management raised 2026 adjusted EPS guidance to $25.00-$25.75 and lifted the revenue growth outlook, signaling the business is performing better than expected.
This is the core new event that directly lifts earnings expectations and the stock.
Vitas hospice drives growth; Roto Rooter lags The Vitas hospice unit beat expectations with 9% more admissions and lower labor costs, boosting revenue and margins. Roto Rooter's plumbing segment was weaker, with fewer leads and a drop in water restoration revenue, but management is reducing its reliance on paid leads.
Explains the operational engine behind the earnings beat and the one soft spot investors should watch.
Dividend raised 17% and buybacks continue Chemed raised its quarterly dividend by 17% to 70 cents per share and is repurchasing shares aggressively, funded by over $173 million in quarterly operating cash flow. Returning more cash to shareholders supports the stock price and signals confidence in future profits.
Shows a concrete new capital return action that supports the shares.
Bearish call flags slow long-term growth A StockStory report named Chemed a healthcare stock to avoid, citing just 4% annual revenue growth and 2.8% EPS growth over five years, plus diminishing returns on capital. This is a counterweight to the upbeat earnings and could cap gains if investors focus on the slow long-term track record.
Provides the main negative view that balances the positive earnings news.

NeoGenomics Inc (NEO)

Q3 20269 Jul – 6 Oct 2026

▲4

NeoGenomics rides new FDA test, raised guidance, and CEO transition

FDA-approved prostate cancer test launch NeoGenomics launched PTEN IHC CDx, the first FDA-approved lab test to identify prostate cancer patients eligible for AstraZeneca's targeted therapy TRUQAP. This new product expands its oncology menu and could drive future testing demand, pushing the stock up 3.4% on the news.
New product launch is a fresh growth driver that directly boosts revenue potential.
Raised 2026 revenue and profit guidance After strong Q2 results, NeoGenomics raised its full-year 2026 revenue outlook to $802–$806 million and lifted adjusted EBITDA guidance to $56–$58 million. Clinical revenue grew 14%, led by a 26% jump in next-generation sequencing, showing the core business is accelerating.
Guidance raise signals stronger-than-expected business momentum, a key positive for the stock.
Preliminary Q3 revenue beats consensus NeoGenomics reported preliminary third-quarter revenue of about $209 million, topping the $205.9 million consensus estimate, with very strong next-generation sequencing growth. The company also plans to raise its full-year guidance, reinforcing confidence in its growth trajectory.
Better-than-expected quarterly revenue and a guidance hike are fresh positive catalysts.
CEO succession and board refresh Warren Stone, current President and COO, will become CEO in January 2027, with current CEO Tony Zook moving to Executive Chair. The planned transition and board expansion aim to support the next phase of growth, which investors took as a positive signal.
Leadership change is a new event that can affect investor confidence and future strategy.

August 20269 Jul – 6 Oct 2026

▲4

NeoGenomics rides new FDA test, raised guidance, and CEO transition

FDA-approved prostate cancer test launch NeoGenomics launched PTEN IHC CDx, the first FDA-approved lab test to identify prostate cancer patients eligible for AstraZeneca's targeted therapy TRUQAP. This new product expands its oncology menu and could drive future testing demand, pushing the stock up 3.4% on the news.
New product launch is a fresh growth driver that directly boosts revenue potential.
Raised 2026 revenue and profit guidance After strong Q2 results, NeoGenomics raised its full-year 2026 revenue outlook to $802–$806 million and lifted adjusted EBITDA guidance to $56–$58 million. Clinical revenue grew 14%, led by a 26% jump in next-generation sequencing, showing the core business is accelerating.
Guidance raise signals stronger-than-expected business momentum, a key positive for the stock.
Preliminary Q3 revenue beats consensus NeoGenomics reported preliminary third-quarter revenue of about $209 million, topping the $205.9 million consensus estimate, with very strong next-generation sequencing growth. The company also plans to raise its full-year guidance, reinforcing confidence in its growth trajectory.
Better-than-expected quarterly revenue and a guidance hike are fresh positive catalysts.
CEO succession and board refresh Warren Stone, current President and COO, will become CEO in January 2027, with current CEO Tony Zook moving to Executive Chair. The planned transition and board expansion aim to support the next phase of growth, which investors took as a positive signal.
Leadership change is a new event that can affect investor confidence and future strategy.

Latest9 Jul – 6 Oct 2026

▲4

NeoGenomics rides new FDA test, raised guidance, and CEO transition

FDA-approved prostate cancer test launch NeoGenomics launched PTEN IHC CDx, the first FDA-approved lab test to identify prostate cancer patients eligible for AstraZeneca's targeted therapy TRUQAP. This new product expands its oncology menu and could drive future testing demand, pushing the stock up 3.4% on the news.
New product launch is a fresh growth driver that directly boosts revenue potential.
Raised 2026 revenue and profit guidance After strong Q2 results, NeoGenomics raised its full-year 2026 revenue outlook to $802–$806 million and lifted adjusted EBITDA guidance to $56–$58 million. Clinical revenue grew 14%, led by a 26% jump in next-generation sequencing, showing the core business is accelerating.
Guidance raise signals stronger-than-expected business momentum, a key positive for the stock.
Preliminary Q3 revenue beats consensus NeoGenomics reported preliminary third-quarter revenue of about $209 million, topping the $205.9 million consensus estimate, with very strong next-generation sequencing growth. The company also plans to raise its full-year guidance, reinforcing confidence in its growth trajectory.
Better-than-expected quarterly revenue and a guidance hike are fresh positive catalysts.
CEO succession and board refresh Warren Stone, current President and COO, will become CEO in January 2027, with current CEO Tony Zook moving to Executive Chair. The planned transition and board expansion aim to support the next phase of growth, which investors took as a positive signal.
Leadership change is a new event that can affect investor confidence and future strategy.